Investigational New Drugs

, Volume 17, Issue 3, pp 271–284 | Cite as

Antiandrogens in Prostate Cancer

  • Phillip Reid
  • Philip Kantoff
  • William Oh


Antiandrogens competitively inhibit ligand binding to the androgen receptor (AR), and are used therapeutically in prostate cancer patients. The AR functions as a ligand dependent transcription factor that transduces androgen binding into increased transcription of androgen dependent genes. AR blockade induces programmed cell death in the vast majority of malignant and benign prostate cancer cells that have not previously been exposed to androgen ablation.

The antiandrogens are divided structurally into the steroidal and non steroidal agents. The biological effects of the steroidal versus nonsteroidal agents are distinguished by differences in their effects on serum testosterone levels, and by their activity at receptors other than the androgen receptor. There is extensive clinical experience in the palliative and curative therapy of prostate cancer using antiandrogens as monotherapy or antiandrogens in combination with luteinizing hormone agonists or surgical castration.

Prolonged therapy with antiandrogens selects for mutations in the AR that change the AR ligand specificity and permits stimulation by ligands that are usually inhibitory. These mutations give insight into one of the means by which prostate cancer progresses despite antiandrogen therapy, and also helps to explain the antiandrogen withdrawal syndrome.

Areas of active research that may affect the future use of antiandrogens include the ongoing evaluation of antiandrogens in combination with 5 alpha reductase inhibitors to achieve AR blockade without inducing castrate testosterone levels. There is also interest in developing selective androgen receptor modulators (SARM) that can achieve AR blockade without causing the increased testosterone levels produced by the nonsteroidal antiandrogens currently in use.

antiandrogens androgen receptor prostate cancer hormonal therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Huggins C, Hodges CV: Studies on prostatic cancer: The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297, 1941Google Scholar
  2. 2.
    The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311(20): 1281–1286, 1984Google Scholar
  3. 3.
    Peeling WB: Phase III studies to compare goserelin (zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 13(suppl 5): 45–52, 1989Google Scholar
  4. 4.
    Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 55262, 1988Google Scholar
  5. 5.
    Zhou Z, Sar M, Simental JA, Lane MV, Wilson EM: A liganddependent bipartite nuclear targeting signal in the human androgen receptor. J Biol Chem 269: 13115–13123, 1994Google Scholar
  6. 6.
    Bourguet W, Ruff M, Chamben P, Gronemeyer H, Morad D: Crystal structure of the ligand-binding domain of the nuclear receptor RXR-α. Nature 375: 377–382, 1995Google Scholar
  7. 7.
    Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick R: A structural role for hormone in the thyroid hormone receptor. Nature 378: 690–697, 1995Google Scholar
  8. 8.
    MacLean HE, Garry LW, Zajac JD: Localization of Functional domains in the Androgen Receptor. J Steroid Biochem Molec Biol 62(4): 233–242, 1997Google Scholar
  9. 9.
    Trapman J, Cleutjens KB: Androgen-regulated gene expression in prostate cancer. Seminars in Cancer Biology 8: 29–36, 1997Google Scholar
  10. 10.
    Kuil CW, Berrevoets CA, Mulder E: Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. J Biol Chem 270: 27569–27576, 1995Google Scholar
  11. 11.
    Kemppainen JA, Malcolm VL, Sar M, Wilson EM: Androgen Receptor Phosphorylation, Turnover, Nuclear Transport and Transcriptional Activation. The Journal of Biological Chemistry 267(2): 968–974, 1992Google Scholar
  12. 12.
    Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Sigler PB: Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352: 497–505, 1991Google Scholar
  13. 13.
    Yeh S, Chang C: Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci 93: 5517–5521, 1996Google Scholar
  14. 14.
    Goldenberg SL, Bruchovsky N: Use of cyproterone acetate in prostate cancer. Urol Clin North Am 18: 111–122, 1991Google Scholar
  15. 15.
    Pavone-Macaluso M, De Voogt HJ, Viggiano G et al.: Comparison of diethylstilbestrol, cyproterone acetate, and medroxyprogesterone acetate in the treatment of advanced prostate cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 136: 624–631, 1986Google Scholar
  16. 16.
    Blake JC, Sawyerr AM, Dooley JS et al.: Severe hepatitis caused by cyproterone acetate. Gut 31: 556-57, 1990Google Scholar
  17. 17.
    Goldenberg SL, Bruchovsky N, Rennie PS et al.: The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. J Urol 140: 1460–1465, 1988Google Scholar
  18. 18.
    Neuman F, Jacobi GH: Antiandrogens in tumor therapy. Clin Oncol 1: 41–65, 1982Google Scholar
  19. 19.
    Mann M, Koller E, Murgo A et al.: Glucocorticoidlike Activity of Megestrol a summary of food and drug administration experience and a review of the literature. Arch Intern Med 157: 1651–1656, 1997Google Scholar
  20. 20.
    Dawson NA, Conaway M, Winer EP et al.: A randomized study comparing standard versus moderately high dose megestrol acetate in advanced porostate cancer: a Cancer and Leukemia Group B study. Proc Annu Meet AmSoc Clin Oncol 14: 618a, 1995Google Scholar
  21. 21.
    Crombie C, Raghavan D, Page J et al.: Phase II study of megestrol acetate for metastatic carcinoma of the prostate. Br J Urol 59: 4436, 1987Google Scholar
  22. 22.
    Liana J, Geller J, Zahyna D, Scheuer S, Tchekmedyian NS: High-dose megestrol acetate in advanced prostate cancer: a Phase II study. Proc Annu Meet Am Soc Clin Oncol 12: 800a, 1993Google Scholar
  23. 23.
    Wong CI, Kelce WR, Sar M, Wilson EM: Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 270: 19998–20003, 1995Google Scholar
  24. 24.
    Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP: Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clinical Cancer Research 3: 1383–1388, 1997Google Scholar
  25. 25.
    Taplin ME, Bubley G, KO YJ, Small EJ et al.: Selection for androgen receptor mutations in prostate cancer treated with androgen antagonist. Journal 59: 2511–2515, 1999Google Scholar
  26. 26.
    Sogani PC, Whitmore WF Jr.: Experience with flutamide in previously untreated patients with advanced prostatic cancer. J Urol 122: 640–643, 1979Google Scholar
  27. 27.
    McLeod DG: Tolerability of Nonsteroidal Antiandrogens in the treatment of advanced prostate cancer. The Oncologist 2: 18–27, 1997Google Scholar
  28. 28.
    Schellhammer P, Sharifi R, Block N et al.: A controlled trial of bicalutamide versus flutamide, each in combination with lutenizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45: 745–752, 1995Google Scholar
  29. 29.
    Dankoff JS: Near fatal liver dysfunction secondary to administration of flutamide for prostate cancer. J Urol 248: 19145, 1992Google Scholar
  30. 30.
    Pratticchizo FA: Acute cholestatic hepatitits secondary to flutamide therapy. Am J Med 96: 392, 1994Google Scholar
  31. 31.
    Gomez J, Dupont A, Cusan L et al.: Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 92: 465–470, 1992Google Scholar
  32. 32.
    Kuhn JM, Billebaud T, Navrati H, Moulonguet A et al.: Prevention of the transient adverse effects of a gonadotropinreleasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 321(7): 423–418, 1989Google Scholar
  33. 33.
    Decensi A, Guarneri D, Paoletti MC et al.: Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Eur J Cancer 27: 1100–1104, 1991Google Scholar
  34. 34.
    Du Plessis DJ: Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. Suppl Urol 37: 20–24, 1991Google Scholar
  35. 35.
    Decensi AU, Boccardo F, Guarneri O, Positano N et al.: Monotherapy with nilutamide, a pure nonsteroidal antiandrogen in untreated patients with metastatic carcinoma of the prostate. The Italian prostatic cancer projecy. J Urol 146: 377–381, 1991Google Scholar
  36. 36.
    Beland G, Elhilali M, Fradet Y et al.: Total androgen ablation: canadian experience. Urol Clin North Am 18: 75–82, 1991Google Scholar
  37. 37.
    Janknegt RA: Total androgen blockade with the use of orchiectomy and nilutamide (anandron) or placebo as treatment of metastatic prostate cancer. Cancer 72: 3874–3877, 1993Google Scholar
  38. 38.
    Blackledge GR: High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology (suppl 1A); 47: 44–47, 1996Google Scholar
  39. 39.
    Pavone-Macaluso M, Voogt HJ, Viggiano G, Barassolo E, Lardennois B, Sylvester R: Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer. J Urol 136(3): 624–631, 1986Google Scholar
  40. 40.
    De Voogt HJ, Smith PH, Pavone-Macaluso M et al.: Cardiovascular side effects of diethylstilbesuol, cyproterone acetate, medroxyprogesterone acetate, and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 135: 303–307, 1986Google Scholar
  41. 41.
    Osborne D, Weaver P, Kaisary A et al.: A comparison of “Zoladex”, diethylstilboestrol (DES) and cyproterone acetate (CPA) in advanced prostate cancer (Abstract). Int Symp Endocr Ther Monaco (Nov 19-21) 1988Google Scholar
  42. 42.
    Kassem NY, Neri RO, Munroe JS: Effect offlutamide, an antiandrogen, on stage D cancer of the prostate. Clin Pharmacol Ther 29: 256, 1981Google Scholar
  43. 43.
    Songani PC, Vagaiwala MR, and Whitmore WF Jr.: Experience with flutamide in patients with advanced prostate cancer without prior endocrine therapy. Cancer 54: 744–750, 1984Google Scholar
  44. 44.
    Chang A, Yeap B, Davis T et al.: Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 14: 2250–2257, 1996Google Scholar
  45. 45.
    Denis L: A new non-steroidal anti-androgen. Prog Clin Biol Res 303: 95–103, 1989Google Scholar
  46. 46.
    Iverson P: Update of monotheray trials with the new antiandrogen, Casodex (ICI 176,334). Eur Urol 26 (suppl 1): 5–9, 1994Google Scholar
  47. 47.
    Bales GT, Chodak GW: A controlled trial ofbicalutamide versus castration in patients with advanced prostate cancer. Urology 47 (Suppl 1A): 38–43, 1996Google Scholar
  48. 48.
    Tyrell CJ, Kaisary AV, Iversen P et al.: A randomized comparison of “Casodex” (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33(5): 447–456, 1998Google Scholar
  49. 49.
    Iversen P, Tyrell CI, Kaisary AV et al.: Casodex (bicalutamide) 150 mg/day monotherapy compared with castration in patients with previously untreated nommetastatic prostate cancer: results from two multicenter trials at a median follow-up or 4 years. Urology 51(3): 389–396, 1998Google Scholar
  50. 50.
    Boccardo F, Rubagotti A, Miglietta L et al.: Bicalutamide (B) monotherapy versus flutamide (F) plus goserelin (G) in prostate cancer (CA) patient (pts). Preliminary results of an Italian Prostate Cancer Group (PONCAP) study (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 16: A 1128, 1997Google Scholar
  51. 51.
    Geller J: Effect of finasteride, a 5 alpha-reductase inhibitor, on prostate tissue androgens and prostate specific antigen. J Clin Endocr Metab 74: 505–508, 1992Google Scholar
  52. 52.
    Goldray D, Weisman Y, Jaccard N et al.: Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl. J Clin Endocrinol Metab 76(2): 288-290, 1993Google Scholar
  53. 53.
    Matzkin H, Chen J, Weisman Y et al.: Prolonged treatment with finasteride (a alpha-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol (Oxf) 37(5): 432-436, 1992Google Scholar
  54. 54.
    Ornstein DK, Rao GS, Johnson B, Charlton ET and Andriole GL: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 48(6): 901–905, 1996Google Scholar
  55. 55.
    Brufsky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I, Kaufman D, Kantoff P: Finasteride and flutamide as potency sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate; Urology 49(6): 913-920, 1997Google Scholar
  56. 56.
    Brodkin D, Oh W, Fontaine-Rothe P, George D et al.: Peripheral androgen ablation therapy (AAT) with finasteride and bicalutamide in advanced prostate cancer. Proc Natl Amer Soc Clin Once 18: 335a, 1999Google Scholar
  57. 57.
    Labrie F, Dupont A, Belanger A, Edmond J, Monfette G: Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci USA 81: 3861–3863, 1984Google Scholar
  58. 58.
    Geller J, Albert JD, Nachtsheim A, Loza D: Comparison of prostate cancer tissue dihydrostestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 132: 693–696, 1984Google Scholar
  59. 59.
    Trachtenberg J: The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue. J Urol 129: 1149–1152, 1983Google Scholar
  60. 60.
    Crawford ED, Eisenberger MS, McLeod DG et al.: A controlled trial ofleuprolide with and without nutamide in prostatic carcinoma. N Eng J Med 321: 419–424, 1989Google Scholar
  61. 61.
    Eisenberger MA, Blumenstein BA, Crawford DE et al.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Eng J Med 339: 1036–1042, 1998Google Scholar
  62. 62.
    Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview or 22 randomized trials with 3283 deaths in 5710 patients. Lancet 346: 265–269, 1995Google Scholar
  63. 63.
    Caubet JF, Tosteson TD, Esther DW et al.: Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49(1): 71–78, 1997Google Scholar
  64. 64.
    Bolla M, Gonzalez D, Warde P, Dubois JB. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295–300, 1997Google Scholar
  65. 65.
    Pilepich MV, Sause WT, Shipley WU et al.: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic cancer: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45: 616–622, 1995Google Scholar
  66. 66.
    Pilepich MV, Winter K, Roach M et al.: Phase III Radiation Therapy Oncology (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol 17: 308a, 1998Google Scholar
  67. 67.
    Labrie F, Cusan L, Gomez JL, et al.: Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44 (6A): 29–37, 1994Google Scholar
  68. 68.
    Pilepich MV, Krall JM, Al-Saffaf M et al.: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45: 616–623, 1995Google Scholar
  69. 69.
    Laverdiere J, Gomez JL, Cusan L et al.: Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37: 247–252, 1997Google Scholar
  70. 70.
    Balaji KC, Rabbani F, Tsai Y Bastar A, Fair WR: Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance. J Urol 161: 4 (suppl): 1307, 1999Google Scholar
  71. 71.
    Zeitman A, Nakfoor B, Prince E et al.: The effects of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: An in vitro and in vivo study. Cancer J Sci Am 3: 31–36, 1997Google Scholar
  72. 72.
    Widmark A, Damber JE, Berg A et al.: Estramustine potentiates the effects of irradiation on the Dunning (R3327) rat prostatic adenocarcinoma. Prostate 24: 79–83, 1994Google Scholar
  73. 73.
    Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormonerefractory prostate cancer. J Clin Oncol 11(8): 1566–1572, 1993Google Scholar
  74. 74.
    Sella A, Flex D, Sulkes A, Baniel J: Antiandrogen withdrawal syndrome with cyproterone acetate. Urology 52: 1091–1093, 1998Google Scholar
  75. 75.
    Huan SD, Gerridzen RG, Yau JC, Stewart DJ: Antiandrogen withdrawal syndrome with nilutamide. Urology 49(4): 632–634, 1997Google Scholar
  76. 76.
    Small EJ, Carroll PR: Prostate specific antigen decline after bicalutamide withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43: 408–410, 1994Google Scholar
  77. 77.
    Dawson NA, McLeod DG: Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the anti-androgen withdrawal syndrome. J Urol 153: 1946–1947, 1995Google Scholar
  78. 78.
    Figg WD, Sartor O, Cooper M: Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 98: 412–414, 1995Google Scholar
  79. 79.
    Small EJ, Srinivas S: The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76(8): 1428–1434, 1995Google Scholar
  80. 80.
    Newmark JR, Hardy DO, Tonb DC et al.: Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci 89: 6319–6323, 1992Google Scholar
  81. 81.
    Gaddipati JP, McLeod DG, Heidenberg HB et al.: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861–2864, 1994Google Scholar
  82. 82.
    Veldscholte J, Berrevoets CA, Brinkman AO et al.: Antiandrogens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31: 2393–2399, 1992Google Scholar
  83. 83.
    Culig, Z, Hobish 4 Cronauer MV, Cato AC et al.: Mutant androgen receptor detected in an advancedstage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7: 1541–1550, 1993Google Scholar
  84. 84.
    Taplin ME, Bubley GJ, Suster TD, Frantz ME et al.: Mutation of the androgen-receptor gene in metastatic androgenindependent prostate cancer. N Engl J Med 332(21): 1393–1398, 1995Google Scholar
  85. 85.
    Taplin ME, Bubley G, KO YJ, Small E et al.: Selection for androgen receptor mutation in prostate cancers treated with androgen antagonist. Cancer Research 59: 2511–2515, 1999Google Scholar
  86. 86.
    Taylor CD, Elson P, Tramp DL: Importance of continued testicular suppression in hormonerefractoly prostate cancer. J Clin Oncol 11: 2167, 1993Google Scholar
  87. 87.
    Morgenfeld E, Darsy G, Cascallar D et al.: Cyproterone: Is it a good choice for disseminated prostate cancer patients previously treated with flutamide combinations. Proc Am Soc Clin Oncol 18: 1340, 1999Google Scholar
  88. 88.
    Osborne JL, Smith DC, Trump DL: Megestrol acetate in the treatment of hormone refractory prostate cancer. Am J Clin Oncol 20(3): 308–310, 1997Google Scholar
  89. 89.
    Dawson NA, Small EJ, Conaway D et al.: Megestrol Acetate in men with hormone-refractory prostate cancer; Prostatespecific antigen response and antiandrogen withdrawal. Proc Amer Soc Clin Oncol 15: 601, 1996Google Scholar
  90. 90.
    Joyce R, Fenton MA, Rode P et al.: High dose bicalutatmide for androgen independent prostate cancer: Effect of prior hormonal therapy. J Urol 159: 149–153, 1998Google Scholar
  91. 91.
    Sher H, Liebertz C, Kelly WK, Mazumdar M et al.: Bicalutamide for advanced prostate cancer: the natural versus treated history ofdisease. J Clin Oncol 15: 2928–2938, 1997Google Scholar
  92. 92.
    Furr BA, Tucker H: The preclinical development ofbicalutamide: pharmacodynamics and mechanism ofaction. Urology( Suppl 1A) 47: 13–25, 1996Google Scholar
  93. 93.
    Geller J, Nelson C, Albert I, Pratt C: Effect of megestrol acetate on uroflow rates in patients with benign prostatic hypertrophy. Urology 14: 5, 1979Google Scholar
  94. 94.
    Boccardo F, Decensi AU, Guarneri D, Martorana G, Fioretto L, Mini E, Macaluso MP: Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric italian study. Cancer Detection and Prevention 15: 6, 1991Google Scholar
  95. 95.
    Soloway M, Schellhammer P, Smith J, Chodak G,Kennealey G: Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. Urology (suppl 1A) 47: 33–37, 1996Google Scholar
  96. 96.
    Kucuk O, Blumenstein B, Moinpour C, Lew D et al.: Phase II trial of Casodex in advanced prostate cancer (CaP) patients who failed conventional hormonal manipulation: a Southwest Oncology Group (SWOG) study (SWOG 9235). Proc Annu Meet Am Soc Clin Oncol 15: 245, 1996Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Phillip Reid
    • 1
  • Philip Kantoff
    • 1
  • William Oh
    • 1
  1. 1.Lank Center for Genitourinary OncologyDana Farber-Partners Cancer CareBostonUSA

Personalised recommendations